

LEGISLATURE OF NEBRASKA
ONE HUNDRED FIFTH LEGISLATURE
SECOND SESSION

LEGISLATIVE BILL 906

FINAL READING

Introduced by Williams, 36; Krist, 10.

Read first time January 08, 2018

Committee: Judiciary

1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to
2 amend section 28-405, Revised Statutes Supplement, 2017; to change
3 provisions relating to the schedules of controlled substances; and
4 to repeal the original section.

5 Be it enacted by the people of the State of Nebraska,

1 Section 1. Section 28-405, Revised Statutes Supplement, 2017, is
2 amended to read:

3 28-405 The following are the schedules of controlled substances
4 referred to in the Uniform Controlled Substances Act, unless specifically
5 contained on the list of exempted products of the Drug Enforcement
6 Administration of the United States Department of Justice as the list
7 existed on November 9, 2017:

8 Schedule I

9 (a) Any of the following opiates, including their isomers, esters,
10 ethers, salts, and salts of isomers, esters, and ethers, unless
11 specifically excepted, whenever the existence of such isomers, esters,
12 ethers, and salts is possible within the specific chemical designation:

- 13 (1) Acetylmethadol;
- 14 (2) Allylprodine;
- 15 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
16 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
- 17 (4) Alphameprodine;
- 18 (5) Alphamethadol;
- 19 (6) Benzethidine;
- 20 (7) Betacetylmethadol;
- 21 (8) Betameprodine;
- 22 (9) Betamethadol;
- 23 (10) Betaprodine;
- 24 (11) Clonitazene;
- 25 (12) Dextromoramide;
- 26 (13) Difenoxyin;
- 27 (14) Diampromide;
- 28 (15) Diethylthiambutene;
- 29 (16) Dimenoxadol;
- 30 (17) Dimepheptanol;
- 31 (18) Dimethylthiambutene;

- 1 (19) Dioxaphetyl butyrate;
- 2 (20) Dipipanone;
- 3 (21) Ethylmethylthiambutene;
- 4 (22) Etonitazene;
- 5 (23) Etoxeridine;
- 6 (24) Furethidine;
- 7 (25) Hydroxypethidine;
- 8 (26) Ketobemidone;
- 9 (27) Levomoramide;
- 10 (28) Levophenacymorphan;
- 11 (29) Morpheridine;
- 12 (30) Noracymethadol;
- 13 (31) Norlevorphanol;
- 14 (32) Normethadone;
- 15 (33) Norpipanone;
- 16 (34) Phenadoxone;
- 17 (35) Phenampromide;
- 18 (36) Phenomorphan;
- 19 (37) Phenoperidine;
- 20 (38) Piritramide;
- 21 (39) Proheptazine;
- 22 (40) Properidine;
- 23 (41) Propiram;
- 24 (42) Racemoramide;
- 25 (43) Trimeperidine;
- 26 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
- 27 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
- 28 piperidine;
- 29 (45) Tilidine;
- 30 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
- 31 phenylpropanamide, its optical and geometric isomers, salts, and salts of

1 isomers;

2 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
3 isomers, salts, and salts of isomers;

4 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
5 optical isomers, salts, and salts of isomers;

6 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
7 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
8 isomers;

9 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
10 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
11 of isomers;

12 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
13 its optical isomers, salts, and salts of isomers;

14 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-
15 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
16 of isomers;

17 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
18 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
19 geometric isomers, salts, and salts of isomers;

20 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
21 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
22 salts, and salts of isomers;

23 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
24 (thenylfentanyl), its optical isomers, salts, and salts of isomers;

25 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
26 propanamide, its optical isomers, salts, and salts of isomers;

27 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
28 piperidinyl)propanamide, its optical isomers, salts, and salts of
29 isomers; and

30 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
31 methylbenzamide.

1 (b) Any of the following opium derivatives, their salts, isomers,
2 and salts of isomers, unless specifically excepted, whenever the
3 existence of such salts, isomers, and salts of isomers is possible within
4 the specific chemical designation:

- 5 (1) Acetorphine;
- 6 (2) Acetyldihydrocodeine;
- 7 (3) Benzylmorphine;
- 8 (4) Codeine methylbromide;
- 9 (5) Codeine-N-Oxide;
- 10 (6) Cyprenorphine;
- 11 (7) Desomorphine;
- 12 (8) Dihydromorphine;
- 13 (9) Drotebanol;
- 14 (10) Etorphine, except hydrochloride salt;
- 15 (11) Heroin;
- 16 (12) Hydromorphinol;
- 17 (13) Methyldesorphine;
- 18 (14) Methyldihydromorphine;
- 19 (15) Morphine methylbromide;
- 20 (16) Morphine methylsulfonate;
- 21 (17) Morphine-N-Oxide;
- 22 (18) Myrophine;
- 23 (19) Nicocodeine;
- 24 (20) Nicomorphine;
- 25 (21) Normorphine;
- 26 (22) Pholcodine; and
- 27 (23) Thebacon.

28 (c) Any material, compound, mixture, or preparation which contains
29 any quantity of the following hallucinogenic substances, their salts,
30 isomers, and salts of isomers, unless specifically excepted, whenever the
31 existence of such salts, isomers, and salts of isomers is possible within

1 the specific chemical designation, and, for purposes of this subdivision
2 only, isomer shall include the optical, position, and geometric isomers:

3 (1) Bufotenine. Trade and other names shall include, but are not
4 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
5 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
6 dimethyltryptamine; and mappine;

7 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
8 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-
9 methylphenethylamine; and 4-bromo-2,5-DMA;

10 (3) 4-methoxyamphetamine. Trade and other names shall include, but
11 are not limited to: 4-methoxy-alpha-methylphenethylamine; and
12 paramethoxyamphetamine, PMA;

13 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
14 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
15 methylphenethylamine; DOM; and STP;

16 (5) Ibogaine. Trade and other names shall include, but are not
17 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
18 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
19 iboga;

20 (6) Lysergic acid diethylamide;

21 (7) Marijuana;

22 (8) Mescaline;

23 (9) Peyote. Peyote shall mean all parts of the plant presently
24 classified botanically as *Lophophora williamsii* Lemaire, whether growing
25 or not, the seeds thereof, any extract from any part of such plant, and
26 every compound, manufacture, salts, derivative, mixture, or preparation
27 of such plant or its seeds or extracts;

28 (10) Psilocybin;

29 (11) Psilocyn;

30 (12) Tetrahydrocannabinols, including, but not limited to, synthetic
31 equivalents of the substances contained in the plant or in the resinous

1 extractives of cannabis, sp. or synthetic substances, derivatives, and
2 their isomers with similar chemical structure and pharmacological
3 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol
4 and their optical isomers, excluding dronabinol ~~in sesame oil and~~
5 ~~encapsulated in a soft gelatin capsule~~ in a drug product approved by the
6 federal Food and Drug Administration; Delta 6 cis or trans
7 tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis or
8 trans tetrahydrocannabinol and its optical isomers. Since nomenclature of
9 these substances is not internationally standardized, compounds of these
10 structures shall be included regardless of the numerical designation of
11 atomic positions covered;

12 (13) N-ethyl-3-piperidyl benzilate;

13 (14) N-methyl-3-piperidyl benzilate;

14 (15) Thiophene analog of phencyclidine. Trade and other names shall
15 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;
16 2-thienyl analog of phencyclidine; TPCP; and TCP;

17 (16) Hashish or concentrated cannabis;

18 (17) Parahexyl. Trade and other names shall include, but are not
19 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
20 dibenzo(b,d)pyran; and Synhexyl;

21 (18) Ethylamine analog of phencyclidine. Trade and other names shall
22 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-
23 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
24 cyclohexamine; and PCE;

25 (19) Pyrrolidine analog of phencyclidine. Trade and other names
26 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-
27 pyrrolidine; PCPy; and PHP;

28 (20) Alpha-ethyltryptamine. Some trade or other names: etryptamine;
29 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
30 alpha-ET; and AET;

31 (21) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;

1 (22) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;

2 (23) Alpha-methyltryptamine, which is also known as AMT;

3 (24) *Salvia divinorum* or Salvinorin A. *Salvia divinorum* or
4 Salvinorin A includes all parts of the plant presently classified
5 botanically as *Salvia divinorum*, whether growing or not, the seeds
6 thereof, any extract from any part of such plant, and every compound,
7 manufacture, derivative, mixture, or preparation of such plant, its
8 seeds, or its extracts, including salts, isomers, and salts of isomers
9 whenever the existence of such salts, isomers, and salts of isomers is
10 possible within the specific chemical designation;

11 (25) Any material, compound, mixture, or preparation containing any
12 quantity of synthetically produced cannabinoids as listed in subdivisions
13 (A) through (L) of this subdivision, including their salts, isomers,
14 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs,
15 unless specifically excepted elsewhere in this section. Since
16 nomenclature of these synthetically produced cannabinoids is not
17 internationally standardized and may continually evolve, these structures
18 or compounds of these structures shall be included under this
19 subdivision, regardless of their specific numerical designation of atomic
20 positions covered, so long as it can be determined through a recognized
21 method of scientific testing or analysis that the substance contains
22 properties that fit within one or more of the following categories:

23 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally
24 contained in a plant of the genus *cannabis* (*cannabis* plant), as well as
25 synthetic equivalents of the substances contained in the plant, or in the
26 resinous extractives of *cannabis*, sp. and/or synthetic substances,
27 derivatives, and their isomers with similar chemical structure and
28 pharmacological activity such as the following: Delta 1 cis or trans
29 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans
30 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans
31 tetrahydrocannabinol, and its optical isomers;

1 (B) Naphthoylindoles: Any compound containing a 3-(1-
2 naphthoyl)indole structure with substitution at the nitrogen atom of the
3 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
4 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
5 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
6 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
7 tetrahydropyranylmethyl group, whether or not further substituted in or
8 on any of the listed ring systems to any extent;

9 (C) Naphthylmethylinindoles: Any compound containing a 1 H-indol-3-
10 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
11 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
12 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
13 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
14 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
15 tetrahydropyranylmethyl group, whether or not further substituted in or
16 on any of the listed ring systems to any extent;

17 (D) Naphthoylpyrroles: Any compound containing a 3-(1-
18 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
19 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
20 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
21 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
22 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
23 tetrahydropyranylmethyl group, whether or not further substituted in or
24 on any of the listed ring systems to any extent;

25 (E) Naphthylideneindenes: Any compound containing a
26 naphthylideneindene structure with substitution at the 3-position of the
27 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
28 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
29 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
30 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
31 tetrahydropyranylmethyl group, whether or not further substituted in or

1 on any of the listed ring systems to any extent;

2 (F) Phenylacetylindoles: Any compound containing a 3-
3 phenylacetylindole structure with substitution at the nitrogen atom of
4 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
5 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
6 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
7 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
8 tetrahydropyranylmethyl group, whether or not further substituted in or
9 on any of the listed ring systems to any extent;

10 (G) Cyclohexylphenols: Any compound containing a 2-(3-
11 hydroxycyclohexyl)phenol structure with substitution at the 5-position of
12 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
13 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
14 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
15 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
16 tetrahydropyranylmethyl group, whether or not substituted in or on any of
17 the listed ring systems to any extent;

18 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole
19 structure with substitution at the nitrogen atom of the indole ring by an
20 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
21 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
22 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
23 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
24 further substituted in or on any of the listed ring systems to any
25 extent;

26 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
27 structure with substitution at the nitrogen atom of the indole ring by an
28 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,
29 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
30 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
31 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not

1 further substituted in or on any of the listed ring systems to any
2 extent;

3 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
4 tetramethylcyclopropanoylindole structure with substitution at the
5 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
6 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
7 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
8 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
9 tetrahydropyranylmethyl group, whether or not further substituted in or
10 on any of the listed ring systems to any extent;

11 (K) Indole carboxamides: Any compound containing a 1-indole-3-
12 carboxamide structure with substitution at the nitrogen atom of the
13 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
14 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
15 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
16 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
17 tetrahydropyranylmethyl group, substitution at the carboxamide group by
18 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
19 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
20 substituted in or on any of the listed ring systems to any extent or to
21 the adamantyl, 1-naphthyl, phenyl, aminooxoalkyl, benzyl, or
22 propionaldehyde groups to any extent;

23 (L) Indole carboxylates: Any compound containing a 1-indole-3-
24 carboxylate structure with substitution at the nitrogen atom of the
25 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
26 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
27 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
28 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
29 tetrahydropyranylmethyl group, substitution at the carboxylate group by
30 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
31 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further

1 substituted in or on any of the listed ring systems to any extent or to
2 the adamantyl, 1-maphthyl, phenyl, aminooxoalkyl, benzyl, or
3 propionaldehyde groups to any extent; and

4 (M) Any nonnaturally occurring substance, chemical compound,
5 mixture, or preparation, not specifically listed elsewhere in these
6 schedules and which is not approved for human consumption by the federal
7 Food and Drug Administration, containing or constituting a cannabinoid
8 receptor agonist as defined in section 28-401;

9 (26) Any material, compound, mixture, or preparation containing any
10 quantity of a substituted phenethylamine as listed in subdivisions (A)
11 through (C) of this subdivision, unless specifically excepted, listed in
12 another schedule, or specifically named in this schedule, that is
13 structurally derived from phenylethan-2-amine by substitution on the
14 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a
15 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by
16 substitution with one alkoxy and either one fused furan, tetrahydrofuran,
17 or tetrahydropyran ring system; or by substitution with two fused ring
18 systems from any combination of the furan, tetrahydrofuran, or
19 tetrahydropyran ring systems, whether or not the compound is further
20 modified in any of the following ways:

21 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
22 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
23 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
24 atom with alkyl, dialkyl, benzyl, hydroxybenzyl or methoxybenzyl groups,
25 and including, but not limited to:

26 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
27 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;

28 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known
29 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;

30 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
31 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;

- 1 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
2 or 2,5-Dimethoxyphenethylamine;
- 3 (v) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
4 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
- 5 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
6 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
- 7 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also
8 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
- 9 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is
10 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
- 11 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is
12 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
- 13 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known
14 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
- 15 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also
16 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
- 17 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also
18 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
- 19 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also
20 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
- 21 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
22 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
- 23 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
24 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
25 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
- 26 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
27 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
28 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
- 29 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
30 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
31 methoxybenzyl)phenethylamine;

- 1 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
2 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
3 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
- 4 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
5 which is also known as 2CB-5-hemiFLY;
- 6 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
7 yl)ethanamine, which is also known as 2C-B-FLY;
- 8 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
9 yl)ethanamine, which is also known as 2C-B-butterFLY;
- 10 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-
11 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
12 NBOMe;
- 13 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
14 which is also known as bromo-benzodifuranylisopropylamine or bromo-
15 dragonFLY;
- 16 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
17 is also known as 2C-INBOH or 25I-NBOH;
- 18 (xxv) 5-(2-Aminopropyl)benzofuran 5-(2-Aminoprpyl)benzofuran, which
19 is also known as 5-APB;
- 20 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
- 21 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known
22 as 5-APDB;
- 23 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also
24 known as 6-APDB;
- 25 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-
26 dimethoxy-a-methylphenethylamine; 2, 5-DMA;
- 27 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
- 28 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also
29 known as 2C-T-7;
- 30 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 31 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as

- 1 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
- 2 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
- 3 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
- 4 MDMA;
- 5 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
- 6 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA; and
- 7 (xxxvii) 3,4,5-trimethoxy amphetamine;
- 8 (27) Any material, compound, mixture, or preparation containing any
- 9 quantity of a substituted tryptamine unless specifically excepted, listed
- 10 in another schedule, or specifically named in this schedule, that is
- 11 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
- 12 known as tryptamine, by mono- or di-substitution of the amine nitrogen
- 13 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
- 14 in a cyclic structure whether or not the compound is further substituted
- 15 at the alpha position with an alkyl group or whether or not further
- 16 substituted on the indole ring to any extent with any alkyl, alkoxy,
- 17 halo, hydroxyl, or acetoxy groups, and including, but not limited to:
- 18 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
- 19 DALT;
- 20 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-
- 21 DMT or OAcetylpsilocin;
- 22 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
- 23 HO-MET;
- 24 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-
- 25 HO-DIPT;
- 26 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
- 27 5-MeOMiPT;
- 28 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
- 29 DMT;
- 30 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
- 31 MeO-DiPT;

1 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
2 DET; and

3 (I) Dimethyltryptamine, which is also known as DMT; and

4 (28)(A) Any substance containing any quantity of the following
5 materials, compounds, mixtures, or structures:

6 (i) 3,4-methylenedioxy methcathinone, or bk-MDMA, or methylone;

7 (ii) 3,4-methylenedioxy pyrovalerone, or MDPV;

8 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;

9 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;

10 (v) Fluoromethcathinone, or FMC;

11 (vi) Naphthylpyrovalerone, or naphyrone; or

12 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
13 butylone; or

14 (B) Unless listed in another schedule, any substance which contains
15 any quantity of any material, compound, mixture, or structure, other than
16 bupropion, that is structurally derived by any means from 2-
17 aminopropan-1-one by substitution at the 1-position with either phenyl,
18 naphthyl, or thiophene ring systems, whether or not the compound is
19 further modified in any of the following ways:

20 (i) Substitution in the ring system to any extent with alkyl,
21 alkoxy, alkylendioxy, haloalkyl, hydroxyl, or halide substituents,
22 whether or not further substituted in the ring system by one or more
23 other univalent substituents;

24 (ii) Substitution at the 3-position with an acyclic alkyl
25 substituent; or

26 (iii) Substitution at the 2-amino nitrogen atom with alkyl or
27 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
28 structure.

29 (d) Unless specifically excepted or unless listed in another
30 schedule, any material, compound, mixture, or preparation which contains
31 any quantity of the following substances having a depressant effect on

1 the central nervous system, including its salts, isomers, and salts of
2 isomers whenever the existence of such salts, isomers, and salts of
3 isomers is possible within the specific chemical designation:

4 (1) Mecloqualone;

5 (2) Methaqualone; and

6 (3) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-
7 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium
8 Oxybate; and Sodium Oxybutyrate.

9 (e) Unless specifically excepted or unless listed in another
10 schedule, any material, compound, mixture, or preparation which contains
11 any quantity of the following substances having a stimulant effect on the
12 central nervous system, including its salts, isomers, and salts of
13 isomers:

14 (1) Fenethylamine;

15 (2) N-ethylamphetamine;

16 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-
17 dihydro-5-phenyl-2-oxazolamine;

18 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-
19 aminopropiophenone; 2-aminopropiophenone; and norephedrone;

20 (5) Methcathinone, its salts, optical isomers, and salts of optical
21 isomers. Some other names: 2-(methylamino)-propionophenone; alpha-
22 (methylamino)propionophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
23 N-methylaminopropionophenone; methylcathinone; monomethylpropion;
24 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; and UR1432;

25 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-
26 phenyl-2-oxazolamine;

27 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
28 and N,N-alpha-trimethylphenethylamine; and

29 (8) Benzylpiperazine, 1-benzylpiperazine.

30 (f) Any controlled substance analogue to the extent intended for
31 human consumption.

1 Schedule II

2 (a) Any of the following substances except those narcotic drugs
3 listed in other schedules whether produced directly or indirectly by
4 extraction from substances of vegetable origin, independently by means of
5 chemical synthesis, or by combination of extraction and chemical
6 synthesis:

7 (1) Opium and opiate, and any salt, compound, derivative, or
8 preparation of opium or opiate, excluding apomorphine, buprenorphine,
9 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmeffene,
10 naloxone, and naltrexone and their salts, but including the following:

- 11 (A) Raw opium;
- 12 (B) Opium extracts;
- 13 (C) Opium fluid;
- 14 (D) Powdered opium;
- 15 (E) Granulated opium;
- 16 (F) Tincture of opium;
- 17 (G) Codeine;
- 18 (H) Ethylmorphine;
- 19 (I) Etorphine hydrochloride;
- 20 (J) Hydrocodone;
- 21 (K) Hydromorphone;
- 22 (L) Metopon;
- 23 (M) Morphine;
- 24 (N) Oxycodone;
- 25 (O) Oxymorphone;
- 26 (P) Oripavine;
- 27 (Q) Thebaine; and
- 28 (R) Dihydroetorphine;

29 (2) Any salt, compound, derivative, or preparation thereof which is
30 chemically equivalent to or identical with any of the substances referred
31 to in subdivision (1) of this subdivision, except that these substances

1 shall not include the isoquinoline alkaloids of opium;

2 (3) Opium poppy and poppy straw;

3 (4) Coca leaves and any salt, compound, derivative, or preparation
4 of coca leaves, and any salt, compound, derivative, or preparation
5 thereof which is chemically equivalent to or identical with any of these
6 substances, including cocaine or ecgonine and its salts, optical isomers,
7 and salts of optical isomers, except that the substances shall not
8 include decocainized coca leaves or extractions which do not contain
9 cocaine or ecgonine; and

10 (5) Concentrate of poppy straw, the crude extract of poppy straw in
11 either liquid, solid, or powder form which contains the phenanthrene
12 alkaloids of the opium poppy.

13 (b) Unless specifically excepted or unless in another schedule any
14 of the following opiates, including their isomers, esters, ethers, salts,
15 and salts of their isomers, esters, and ethers whenever the existence of
16 such isomers, esters, ethers, and salts is possible within the specific
17 chemical designation, dextrorphan excepted:

18 (1) Alphaprodine;

19 (2) Anileridine;

20 (3) Bezitramide;

21 (4) Diphenoxylate;

22 (5) Fentanyl;

23 (6) Isomethadone;

24 (7) Levomethorphan;

25 (8) Levorphanol;

26 (9) Metazocine;

27 (10) Methadone;

28 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
29 butane;

30 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
31 diphenylpropane-carboxylic acid;

- 1 (13) Pethidine or meperidine;
- 2 (14) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 3 (15) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
- 4 carboxylate;
- 5 (16) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
- 6 carboxylic acid;
- 7 (17) Phenazocine;
- 8 (18) Piminodine;
- 9 (19) Racemethorphan;
- 10 (20) Racemorphan;
- 11 (21) Dihydrocodeine;
- 12 (22) Bulk Propoxyphene in nondosage forms;
- 13 (23) Sufentanil;
- 14 (24) Alfentanil;
- 15 (25) Levo-alphaacetylmethadol which is also known as levo-alpha-
- 16 acetylmethadol, levomethadyl acetate, and LAAM;
- 17 (26) Carfentanil;
- 18 (27) Remifentanil;~~and~~
- 19 (28) Tapentadol; and -
- 20 (29) Thiafentanil.
- 21 (c) Any material, compound, mixture, or preparation which contains
- 22 any quantity of the following substances having a potential for abuse
- 23 associated with a stimulant effect on the central nervous system:
- 24 (1) Amphetamine, its salts, optical isomers, and salts of its
- 25 optical isomers;
- 26 (2) Phenmetrazine and its salts;
- 27 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
- 28 (4) Methylphenidate; and
- 29 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
- 30 (d) Any material, compound, mixture, or preparation which contains
- 31 any quantity of the following substances having a potential for abuse

1 associated with a depressant effect on the central nervous system,
2 including their salts, isomers, and salts of isomers whenever the
3 existence of such salts, isomers, and salts of isomers is possible within
4 the specific chemical designations:

- 5 (1) Amobarbital;
- 6 (2) Secobarbital;
- 7 (3) Pentobarbital;
- 8 (4) Phencyclidine; and
- 9 (5) Glutethimide.

10 (e) Hallucinogenic substances known as:

- 11 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
12 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
13 dibenzo(b,d)pyran-9-one; and -

14 (2) Dronabinol in an oral solution in a drug product approved by the
15 federal Food and Drug Administration.

16 (f) Unless specifically excepted or unless listed in another
17 schedule, any material, compound, mixture, or preparation which contains
18 any quantity of the following substances:

- 19 (1) Immediate precursor to amphetamine and methamphetamine:
20 Phenylacetone. Trade and other names shall include, but are not limited
21 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
22 ketone;

23 (2) Immediate precursors to phencyclidine, PCP:

- 24 (A) 1-phenylcyclohexylamine; or
- 25 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or

26 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethyl-4-
27 piperidine (ANNPP).

28 Schedule III

29 (a) Any material, compound, mixture, or preparation which contains
30 any quantity of the following substances having a potential for abuse
31 associated with a stimulant effect on the central nervous system,

1 including their salts, isomers, whether optical, position, or geometric,
2 and salts of such isomers whenever the existence of such salts, isomers,
3 and salts of isomers is possible within the specific chemical
4 designation:

- 5 (1) Benzphetamine;
- 6 (2) Chlorphentermine;
- 7 (3) Clortermine; and
- 8 (4) Phendimetrazine.

9 (b) Any material, compound, mixture, or preparation which contains
10 any quantity of the following substances having a potential for abuse
11 associated with a depressant effect on the central nervous system:

12 (1) Any substance which contains any quantity of a derivative of
13 barbituric acid or any salt of a derivative of barbituric acid, except
14 those substances which are specifically listed in other schedules of this
15 section;

- 16 (2) Chlorhexadol;
- 17 (3) Embutramide;
- 18 (4) Lysergic acid;
- 19 (5) Lysergic acid amide;
- 20 (6) Methyprylon;
- 21 (7) Perampanel;
- 22 (8) Sulfondiethylmethane;
- 23 (9) Sulfonethylmethane;
- 24 (10) Sulfonmethane;
- 25 (11) Nalorphine;

26 (12) Any compound, mixture, or preparation containing amobarbital,
27 secobarbital, pentobarbital, or any salt thereof and one or more other
28 active medicinal ingredients which are not listed in any schedule;

29 (13) Any suppository dosage form containing amobarbital,
30 secobarbital, pentobarbital, or any salt of any of these drugs and
31 approved by the federal Food and Drug Administration for marketing only

1 as a suppository;

2 (14) Any drug product containing gamma-hydroxybutyric acid,
3 including its salts, isomers, and salts of isomers, for which an
4 application is approved under section 505 of the Federal Food, Drug, and
5 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;

6 (15) Ketamine, its salts, isomers, and salts of isomers. Some other
7 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-
8 cyclohexanone; and

9 (16) Tiletamine and zolazepam or any salt thereof. Trade or other
10 names for a tiletamine-zolazepam combination product shall include, but
11 are not limited to: telazol. Trade or other names for tiletamine shall
12 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-
13 cyclohexanone. Trade or other names for zolazepam shall include, but are
14 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
15 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrzapon.

16 (c) Unless specifically excepted or unless listed in another
17 schedule:

18 (1) Any material, compound, mixture, or preparation containing
19 limited quantities of any of the following narcotic drugs, or any salts
20 calculated as the free anhydrous base or alkaloid, in limited quantities
21 as set forth below:

22 (A) Not more than one and eight-tenths grams of codeine per one
23 hundred milliliters or not more than ninety milligrams per dosage unit,
24 with an equal or greater quantity of an isoquinoline alkaloid of opium;

25 (B) Not more than one and eight-tenths grams of codeine per one
26 hundred milliliters or not more than ninety milligrams per dosage unit,
27 with one or more active, nonnarcotic ingredients in recognized
28 therapeutic amounts;

29 (C) Not more than one and eight-tenths grams of dihydrocodeine per
30 one hundred milliliters or not more than ninety milligrams per dosage
31 unit, with one or more active, nonnarcotic ingredients in recognized

1 therapeutic amounts;

2 (D) Not more than three hundred milligrams of ethylmorphine per one
3 hundred milliliters or not more than fifteen milligrams per dosage unit,
4 with one or more active, nonnarcotic ingredients in recognized
5 therapeutic amounts;

6 (E) Not more than five hundred milligrams of opium per one hundred
7 milliliters or per one hundred grams, or not more than twenty-five
8 milligrams per dosage unit, with one or more active, nonnarcotic
9 ingredients in recognized therapeutic amounts; and

10 (F) Not more than fifty milligrams of morphine per one hundred
11 milliliters or per one hundred grams with one or more active, nonnarcotic
12 ingredients in recognized therapeutic amounts; and

13 (2) Any material, compound, mixture, or preparation containing any
14 of the following narcotic drug or its salts, as set forth below:

15 (A) Buprenorphine.

16 (d) Unless contained on the list of exempt anabolic steroids of the
17 Drug Enforcement Administration of the United States Department of
18 Justice as the list existed on November 9, 2017 ~~January 1, 2014~~, any
19 anabolic steroid, which shall include any material, compound, mixture, or
20 preparation containing any quantity of the following substances,
21 including its salts, isomers, and salts of isomers whenever the existence
22 of such salts of isomers is possible within the specific chemical
23 designation:

24 (1) 3-beta,17-dihydroxy-5a-androstane;

25 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;

26 (3) 5-alpha-androstan-3,17-dione;

27 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-
28 ene);

29 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-
30 ene);

31 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);

- 1 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
- 2 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
- 3 (9) 4-androstenedione (androst-4-en-3,17-dione);
- 4 (10) 5-androstenedione (androst-5-en-3,17-dione);
- 5 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
- 6 hydroxyandrost-4-en-3-one);
- 7 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
- 8 (13) Boldione (androsta-1,4-diene-3,17-3-one);
- 9 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-
- 10 en-3-one);
- 11 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
- 12 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
- 13 alpha-methyl-androst-1,4-dien-3-one);
- 14 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
- 15 en-17-beta-ol) (a.k.a. 'madol');
- 16 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
- 17 hydroxy-5-alpha-androst-1-en-3-one);
- 18 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
- 19 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
- 20 androstan-3-one);
- 21 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
- 22 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
- 23 dihydroxyandrost-4-en-3-one);
- 24 (23) Formebolone (formebolone); (2-formyl-17-alpha-methyl-11-
- 25 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
- 26 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostan[2,3-c]-
- 27 furazan);
- 28 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
- 29 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
- 30 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
- 31 one);

- 1 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
2 one);
- 3 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
4 one);
- 5 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
6 dien-3-one);
- 7 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
8 ene);
- 9 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-
10 beta-ol-3-one);
- 11 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-
12 one);
- 13 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
- 14 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
- 15 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
- 16 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-
17 hydroxy-17-beta-hydroxyestr-4-en-3-one);
- 18 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
19 dien-3-one);
- 20 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
21 trien-3-one);
- 22 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
23 en-3-one);
- 24 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-
25 en-3-one);
- 26 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-
27 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-
28 methyl-1-testosterone');
- 29 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
- 30 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
- 31 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);

- 1 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
2 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
3 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
4 dione);
5 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
6 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
7 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
8 en-3-one);
9 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
10 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
11 one);
12 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
13 one);
14 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
15 androstan-3-one);
16 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
17 en-3-one);
18 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
19 hydroxy-[5-alpha]-androstan-3-one);
20 (58) Prostanazol (17-beta-hydroxy-5-alpha-androstano[3,2-
21 c]pyrazole);
22 (59) Stanazolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
23 androst-2-eno[3,2-c]-pyrazole);
24 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
25 one);
26 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
27 oic acid lactone);
28 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
29 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
30 hydroxygon-4,9,11-trien-3-one);
31 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one); and

1 (65) Any salt, ester, or ether of a drug or substance described or
2 listed in this subdivision if the salt, ester, or ether promotes muscle
3 growth.

4 (e) Hallucinogenic substances known as:

5 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
6 gelatin capsule in a drug product approved by the federal Food and Drug
7 Administration. Some other names for dronabinol are (6aR-
8 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
9 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.

10 Schedule IV

11 (a) Any material, compound, mixture, or preparation which contains
12 any quantity of the following substances, including their salts, isomers,
13 and salts of isomers whenever the existence of such salts, isomers, and
14 salts of isomers is possible within the specific chemical designation:

15 (1) Barbital;

16 (2) Chloral betaine;

17 (3) Chloral hydrate;

18 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide
19 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and
20 water soluble esterified estrogens);

21 (5) Clonazepam;

22 (6) Clorazepate;

23 (7) Diazepam;

24 (8) Ethchlorvynol;

25 (9) Ethinamate;

26 (10) Flurazepam;

27 (11) Mebutamate;

28 (12) Meprobamate;

29 (13) Methohexital;

30 (14) Methylphenobarbital;

31 (15) Oxazepam;

- 1 (16) Paraldehyde;
- 2 (17) Petrichloral;
- 3 (18) Phenobarbital;
- 4 (19) Prazepam;
- 5 (20) Alprazolam;
- 6 (21) Bromazepam;
- 7 (22) Camazepam;
- 8 (23) Clobazam;
- 9 (24) Clotiazepam;
- 10 (25) Cloxazolam;
- 11 (26) Delorazepam;
- 12 (27) Estazolam;
- 13 (28) Ethyl loflazepate;
- 14 (29) Fludiazepam;
- 15 (30) Flunitrazepam;
- 16 (31) Halazepam;
- 17 (32) Haloxazolam;
- 18 (33) Ketazolam;
- 19 (34) Loprazolam;
- 20 (35) Lorazepam;
- 21 (36) Lormetazepam;
- 22 (37) Medazepam;
- 23 (38) Nimetazepam;
- 24 (39) Nitrazepam;
- 25 (40) Nordiazepam;
- 26 (41) Oxazolam;
- 27 (42) Pinazepam;
- 28 (43) Temazepam;
- 29 (44) Tetrazepam;
- 30 (45) Triazolam;
- 31 (46) Midazolam;

- 1 (47) Quazepam;
- 2 (48) Zolpidem;
- 3 (49) Dichloralphenazone;
- 4 (50) Zaleplon;
- 5 (51) Zopiclone;
- 6 (52) Fospropofol;
- 7 (53) Alfaxalone;
- 8 (54) Suvorexant; and
- 9 (55) Carisoprodol.

10 (b) Any material, compound, mixture, or preparation which contains
11 any quantity of the following substance, including its salts, isomers,
12 whether optical, position, or geometric, and salts of such isomers,
13 whenever the existence of such salts, isomers, and salts of isomers is
14 possible: Fenfluramine.

15 (c) Unless specifically excepted or unless listed in another
16 schedule, any material, compound, mixture, or preparation which contains
17 any quantity of the following substances having a stimulant effect on the
18 central nervous system, including their salts, isomers, whether optical,
19 position, or geometric, and salts of such isomers whenever the existence
20 of such salts, isomers, and salts of isomers is possible within the
21 specific chemical designation:

- 22 (1) Diethylpropion;
- 23 (2) Phentermine;
- 24 (3) Pemoline, including organometallic complexes and chelates
25 thereof;
- 26 (4) Mazindol;
- 27 (5) Pipradrol;
- 28 (6) SPA, ((-)-1-dimethylamino- 1,2-diphenylethane);
- 29 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
- 30 (8) Fencamfamin;
- 31 (9) Fenproporex;

1 (10) Mefenorex;

2 (11) Modafinil; and

3 (12) Sibutramine.

4 (d) Unless specifically excepted or unless listed in another
5 schedule, any material, compound, mixture, or preparation which contains
6 any quantity of the following narcotic drugs, or their salts or isomers
7 calculated as the free anhydrous base or alkaloid, in limited quantities
8 as set forth below:

9 (1) Propoxyphene in manufactured dosage forms;

10 (2) Not more than one milligram of difenoxin and not less than
11 twenty-five micrograms of atropine sulfate per dosage unit; and

12 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
13 salts, optical and geometric isomers, and salts of these isomers to
14 include: Tramadol.

15 (e) Unless specifically excepted or unless listed in another
16 schedule, any material, compound, mixture, or preparation which contains
17 any quantity of the following substance, including its salts:

18 (1) Pentazocine; and

19 (2) Butorphanol (including its optical isomers).

20 (f) Any material, compound, mixture, or preparation which contains
21 any quantity of the following substances, including its salts, isomers,
22 and salts of such isomers, whenever the existence of such salts, isomers,
23 and salts of isomers is possible: Lorcaserin.

24 (g)(1) Unless specifically excepted or unless listed in another
25 schedule, any material, compound, mixture, or preparation which contains
26 any quantity of the following substance, including its salts, optical
27 isomers, and salts of such optical isomers: Ephedrine.

28 (2) The following drug products containing ephedrine, its salts,
29 optical isomers, and salts of such optical isomers, are excepted from
30 subdivision (g)(1) of Schedule IV if they (A) are stored behind a
31 counter, in an area not accessible to customers, or in a locked case so

1 that a customer needs assistance from an employee to access the drug
2 product; (B) are sold by a person, eighteen years of age or older, in the
3 course of his or her employment to a customer eighteen years of age or
4 older with the following restrictions: No customer shall be allowed to
5 purchase, receive, or otherwise acquire more than three and six-tenths
6 grams of ephedrine base during a twenty-four-hour period; no customer
7 shall purchase, receive, or otherwise acquire more than nine grams of
8 ephedrine base during a thirty-day period; and the customer shall display
9 a valid driver's or operator's license, a Nebraska state identification
10 card, a military identification card, an alien registration card, or a
11 passport as proof of identification; (C) are labeled and marketed in a
12 manner consistent with the pertinent OTC Tentative Final or Final
13 Monograph; (D) are manufactured and distributed for legitimate medicinal
14 use in a manner that reduces or eliminates the likelihood of abuse; and
15 (E) are not marketed, advertised, or represented in any manner for the
16 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or
17 high, heightened sexual performance, or increased muscle mass:

- 18 (i) Primatene Tablets; and
19 (ii) Bronkaid Dual Action Caplets.

20 Schedule V

21 (a) Any compound, mixture, or preparation containing any of the
22 following limited quantities of narcotic drugs or salts calculated as the
23 free anhydrous base or alkaloid, which shall include one or more
24 nonnarcotic active medicinal ingredients in sufficient proportion to
25 confer upon the compound, mixture, or preparation valuable medicinal
26 qualities other than those possessed by the narcotic drug alone:

- 27 (1) Not more than two hundred milligrams of codeine per one hundred
28 milliliters or per one hundred grams;
29 (2) Not more than one hundred milligrams of dihydrocodeine per one
30 hundred milliliters or per one hundred grams;
31 (3) Not more than one hundred milligrams of ethylmorphine per one

1 hundred milliliters or per one hundred grams;

2 (4) Not more than two and five-tenths milligrams of diphenoxylate
3 and not less than twenty-five micrograms of atropine sulfate per dosage
4 unit;

5 (5) Not more than one hundred milligrams of opium per one hundred
6 milliliters or per one hundred grams; and

7 (6) Not more than five-tenths milligram of difenoxin and not less
8 than twenty-five micrograms of atropine sulfate per dosage unit.

9 (b) Unless specifically exempted or excluded or unless listed in
10 another schedule, any material, compound, mixture, or preparation which
11 contains any quantity of the following substances having a stimulant
12 effect on the central nervous system, including its salts, isomers, and
13 salts of isomers: Pyrovalerone.

14 (c) Unless specifically exempted or excluded or unless listed in
15 another schedule, any material, compound, mixture, or preparation which
16 contains any quantity of the following substances having a depressant
17 effect on the central nervous system, including its salts, isomers, and
18 salts of isomers:

19 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
20 acid ethyl ester);

21 (2) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);
22 and

23 (3) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid); and

24 (4) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
25 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
26 salts.

27 (d) Cannabidiol in a drug product approved by the federal Food and
28 Drug Administration.

29 Sec. 2. Original section 28-405, Revised Statutes Supplement, 2017,
30 is repealed.